Therapeutic adjuvant

a technology of adjuvants and adjuvants, applied in the field of therapeutic adjuvants, can solve the problems of/or diagnostics, affecting the effect of subsequent therapies, and unable to demonstrate meaningful therapeutic benefits, etc., to achieve enhancement or production of effective immune responses, enhance effective immune responses, and enhance effective immune responses

Inactive Publication Date: 2005-12-08
ALTAREX MEDICAL
View PDF13 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for improved effectiveness against diseases caused by bacteria called pseudomonas aeruginosa through use of special type of antigens like those found on mice infected with this organism. These types of antisera help fight off other germs causing illnesses while still being able to stimulate strong responses when given them to patients who have been previously exposed to these microorganisms.

Problems solved by technology

The technical problem addressed in this patented text relates to improving methods for treatments involving excessive production of certain proteins called autoantigens like those involved in allergies such as house dust mite allergy. These can cause severe symptoms including skin rashes, itchiness, swelling around blood vessels on the fingers, asthma attacks, etcetera. Therefore there has been an interest in finding ways to prevent these harm caused by their use without affecting other healthy tissues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic adjuvant
  • Therapeutic adjuvant
  • Therapeutic adjuvant

Examples

Experimental program
Comparison scheme
Effect test

examples

[0111] The following examples are intended to further illustrate certain particularly preferred embodiments of the invention and are not intended to limit the scope of the invention. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application) are hereby expressly incorporated by reference.

[0112] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, microbiology and recombinant DNA, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B.

example i

Effect Of HAMA On Antigen Uptake By Dendritic Cells

[0113] Complexation of antibody with specific antigen or with HAMA and binding to dendritic cells was measured. To do this, human anti-mouse antibody (HAMA) was purified from patient serum samples with high HAMA concentrations after MAb Alt-2 injection via affinity chromatography on Protein G, and a MAb-Alt-1 column (Alt-1 specifically binds to the MUC-1 antigen) to eliminate Ab2 (i.e., human antibody that binds to the idiotype of the MAb Alt-2 antibody).

[0114] Five micrograms (5 μg) of fluorescein (FITC)-labeled Alt-2 (anti-CA125) or Alt-6 (anti-PSA) murine monoclonal antibody was incubated together with the corresponding antigen (1μg) and / or HAMA (2.5 μg) and 5×105 immature dendritic cells at 37° C. for 60 minutes. The mixture was then washed once and resuspended in 0.5% formalin+PBS and subjected to flow cytometry (FACScan) on a FACSCalibur machine (Becton-Dickinson).

[0115] As shown in FIG. 1, antibody plus antigen bound to den

example ii

Effect Of HAMA On Antigen Uptake By Monocytes

[0118] In another experiment, CA125 or MAb-Alt-2 was labeled with FITC and incubated at 1000 U / ml of CA125 and 1 μg / ml of MAb-Alt-2 with monocytes for 1 hour at 37° C. The binding studies were conducted in the absence and presence of HAMA at three concentrations. The binding to cells was assessed by flow cytometry.

[0119] As shown in FIGS. 3A and 3B, both the CA125 antigen as well as the Alt-2 murine monoclonal antibody are taken up more efficiently in the presence of HAMA. FIG. 3A shows the increase in the number of monocytes bound by either FITC-labeled CA125 or FITC labeled Alt-2 in the presence of 0, 0.33, 1, or 2 μg / ml HAMA; FIG. 3B shows the increase in overall fluorescence per cell.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Body weightaaaaaaaaaa
Login to view more

Abstract

Disclosed are methods for enhancing an immune response associated with a disease or condition in a patient comprising administering a first composition comprising a non-specific xenotypic antibody and optionally further administering a second composition comprising a specific xenotypic antibody that specifically binds to an antigen associated with the disease or condition.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner ALTAREX MEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products